Rep. Matt Sabourin dit Choinière

Maddy summaryHB 1382 requires non-military overseas voters in New Hampshire who qualify under the Uniformed and Overseas Citizens Absentee Voting Act (UOCAVA) to submit proof of U.S. citizenship once to maintain voter eligibility. It directly affects U.S. citizens living abroad who are not active-duty military members or their families, mandating submission of documents like passports, birth certificates, or citizenship certificates by January 1, 2027. Military members and their families are exempt from this requirement, as specified in federal UOCAVA law. The New Hampshire Secretary of State will verify submissions through a secure portal or mail, update voter records upon confirmation, and provide education materials to affected voters. This bill aims to verify voter eligibility under state law while maintaining federal voting rights protections for military voters.

Maddy summaryHB 1746 requires public bodies and agencies to make records from investigations funded by taxpayer money publicly accessible under New Hampshire's right-to-know law (RSA 91-A). It directly affects state and local government entities conducting such investigations. The key provision mandates disclosure of all findings, conclusions, and factual summaries, with redactions permitted only for specific privacy protections like FERPA or HIPAA, and strictly limited to what federal or state law requires. Public officials' personal privacy rights in these investigations are waived, and materials cannot be withheld entirely based on privacy exemptions.

Maddy summaryHB 1796 creates a regulated program allowing the therapeutic use of psilocybin in clinical settings to treat specific medical conditions, including treatment-resistant depression, PTSD, substance use disorders, and end-of-life care. The bill requires the Department of Health and Human Services to establish a regulatory board and license qualified medical providers, cultivation facilities, and testing laboratories. It sets standards for administration sessions (including preparation, the session itself, and integration) and mandates reporting of adverse events. This program will make psilocybin treatment available to eligible patients under medical supervision in approved settings.